Skip to content
Biodatica
Start free

IRCCS San Raffaele

Rome, Lazio

OncologyCAR-TPhase III
Compare Sign in to watch

What changed

Phase III trial registered: Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

7mo agoTrial registeredDec 22, 2025Source filing (opens the source filing in a new tab)

Momentum

64no change

Momentum 64 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

672 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2/PHASE3 registered

    Jan 15, 2026

    Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease · NOT_YET_RECRUITING · sponsor: Bambino Gesù Hospital and Research Institute · Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

    ClinicalTrials.gov · NCT07297914 (opens the source filing in a new tab)

  2. Trial

    PHASE1/PHASE2 registered

    Jan 5, 2018

    Neuroblastoma, Neuroblastoma Recurrent, GD2-positive Solid Tumors, Osteosarcoma, Ewing Sarcoma, Sarcoma · ACTIVE_NOT_RECRUITING · sponsor: Bambino Gesù Hospital and Research Institute · Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

    ClinicalTrials.gov · NCT03373097 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Nov 6, 2015

    Chronic Granulomatous Disease X-linked (X-CGD) · RECRUITING · sponsor: IRCCS San Raffaele · Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

    ClinicalTrials.gov · NCT03055247 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources